Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G06F-019/00
A61B-017/3203
A61B-019/00
출원번호
US-0290665
(2008-10-31)
등록번호
US-8762067
(2014-06-24)
발명자
/ 주소
Boyden, Edward S.
Cook, Daniel B.
Hyde, Roderick A.
Leuthardt, Eric C.
Myhrvold, Nathan P.
Sweeney, Elizabeth A.
Wood, Jr., Lowell L.
출원인 / 주소
The Invention Science Fund I, LLC
인용정보
피인용 횟수 :
1인용 특허 :
173
초록▼
Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particula
Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.
대표청구항▼
1. A computer-implemented method, comprising: administering with a predetermined velocity a plurality of frozen particle compositions, including at least two subsets including different therapeutic or reinforcement agents and at least one tracer agent, to at least one surface of at least one biologi
1. A computer-implemented method, comprising: administering with a predetermined velocity a plurality of frozen particle compositions, including at least two subsets including different therapeutic or reinforcement agents and at least one tracer agent, to at least one surface of at least one biological tissue of a subject in a manner sufficient to abrade the at least one surface of the at least one biological tissue;comparing, using one or more microprocessors, information regarding at least one aspect of cellular or tissue abrasion or ablation of the at least one biological tissue of at least one subject, and information regarding at least one clinical outcome following receipt by the at least one subject of the plurality of frozen particle compositions;measuring a signal from the at least one tracer agent;communicating real-time feedback control of the amount of a frozen particle composition delivered to the at least one subject based on the measurement of the signal from the at least one tracer agent; andproviding output information, including at least one of a response signal, a comparison code, a comparison plot, a diagnostic code, a treatment code, a test code, a code indicative of at least one treatment received, a code indicative of at least one prescribed treatment step, a code indicative of at least one vaccination delivered; a code indicative of at least one therapeutic agent delivered; a code indicative of at least one diagnostic agent delivered; a code indicative of at least one interaction of a delivered agent and at least one biological or chemical agent in the subject; a code indicative of at least one dispersion or location of at least one delivered agent; a code indicative of at least one detection material delivered; a code indicative of the depth of penetration of a delivered agent; or a code indicative of the condition of at least one location of an administered frozen particle composition. 2. The method of claim 1, further including determining, using one or more microprocessors, at least one statistical correlation. 3. The method of claim 1, further including counting the occurrence of at least one clinical outcome, using one or more microprocessors. 4. The method of claim 1, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding quantity of cells or tissue removed or destroyed. 5. The method of claim 1, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding at least one dimension of cellular, tissue, or other material removal or destruction. 6. The method of claim 5, wherein information regarding the at least one dimension of cellular, tissue, or other material removal or destruction includes information regarding at least one of depth, width, or breadth of cellular, tissue, or other material removal or destruction. 7. The method of claim 1, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding two or more subjects with one or more common attributes. 8. The method of claim 7, wherein the one or more common attributes include genetic attributes, mental attributes, or psychological attributes. 9. The method of claim 8, wherein the one or more common attributes include genotype attributes or phenotype attributes. 10. The method of claim 9, wherein the one or more common attributes include at least one of height; weight; medical diagnosis; familial background; results on one or more medical tests; ethnic background; body mass index; age; presence or absence of at least one disease or condition; species; ethnicity; race; allergies; gender; thickness of epidermis; thickness of dermis; thickness of stratum corneum; keratin deposition; collagen deposition; blood vessel condition; skin condition; hair or fur condition; muscle condition; tissue condition; organ condition; nerve condition; brain condition; presence or absence of at least one biological, chemical, or therapeutic agent in the subject; pregnancy status; lactation status; genetic profile; proteomic profile; partial or whole genetic sequence; partial or whole proteomic sequence; medical history; lymph condition, or blood condition. 11. The method of claim 1, wherein the at least one aspect of cellular or tissue abrasion or ablation includes information regarding at least one cellular or tissue source. 12. The method of claim 11, wherein the information regarding at least one tissue source includes information regarding at least one abnormal cellular or tissue source. 13. The method of claim 11, wherein the information regarding at least one cellular or tissue source includes information regarding at least one type of cell or tissue. 14. The method of claim 1, wherein the at least one frozen particle composition includes at least one of polyethylene glycol, acetone, ethyl acetate, dimethyl sulfoxide, dimethyl formamide, dioxane, hexamethylphosphorotriamide, perfluorohydrocarbon, methanol, ethanol, tert-butyl alcohol, formic acid, hydrogen fluoride, ammonia, acetic acid, benzene, carbon tetrachloride, acetonitrile, hexane, methylene chloride, carboxylic acid, saline, Ringer's solution, lactated Ringer's solution, Hartmann's solution, acetated Ringer's solution, phosphate buffered solution, TRIS-buffered saline solution, Hank's balanced salt solution, Earle's balanced salt solution, standard saline citrate, HEPES-buffered saline, dextrose, glucose, diethyl ether, nitrogen, carbon dioxide, hydrogen oxide, helium, neon, xenon, krypton, chlorine, bromine, oxygen, air or argon. 15. The method of claim 1, wherein the at least one frozen particle composition includes at least one major dimension of approximately one centimeter or less, approximately one millimeter or less, approximately one micrometer or less, approximately one nanometer or less, or any value therebetween. 16. The method of claim 1, wherein at least one frozen particle composition of the plurality includes one or more reinforcement agents. 17. The method of claim 1, wherein at least one frozen particle composition of the plurality includes one or more explosive materials. 18. The method of claim 1, wherein the receipt by the at least one subject of at least one frozen particle composition is pursuant to at least one clinical trial. 19. The method of claim 1, further including creating, using one or more microprocessors, at least one inclusion criterion and at least one exclusion criterion for a clinical trial involving at least one frozen particle composition of the plurality. 20. The method of claim 1, wherein comparing, using one or more microprocessors, the information further includes suggesting, using one or more microprocessors, the inclusion of one or more of the at least one subject in at least one clinical trial. 21. The method of claim 1, wherein comparing, using one or more microprocessors, the information further includes suggesting, using one or more microprocessors, the exclusion of one or more of the at least one subject in at least one clinical trial. 22. The method of claim 1, further including using one or more of the at least one correlation to predict at least one clinical outcome regarding at least one second subject. 23. The method of claim 22, wherein the at least one second subject has not received the plurality of frozen particle compositions. 24. The method of claim 22, wherein the at least one second subject is a plurality of people; and further including segregating subject identifiers associated with the plurality of people in reference to the predicted at least one clinical outcome. 25. The method of claim 22, wherein the at least one second subject is a plurality of people; and further including determining the eligibility of the at least one second subject for at least one clinical trial. 26. The method of claim 1, further including selecting, using one or more microprocessors, the combination of at least two parameters selected from quality or quantity related to one or more frozen particle compositions; method of delivery of one or more frozen particle compositions; delivery location of one or more frozen particle compositions; content of one or more frozen particle compositions; timing of delivery of one or more frozen particle compositions; decrease in physical dimension of one or more frozen particle compositions; or time interval between at least two deliveries with one or more frozen particle compositions; prior to delivering the one or more frozen particle compositions. 27. The method of claim 26, further including communicating selecting information, using one or more microprocessors, to a frozen particle composition selecting apparatus, a frozen particle composition generating apparatus, or both. 28. A computer-implemented method of predicting a clinical outcome of at least one frozen particle composition treatment for at least one first subject, comprising: administering with a predetermined velocity a plurality of frozen particle compositions including at least two subsets including different therapeutic or reinforcement agents and at least one tracer agent; to at least one surface of at least one biological tissue of a subject in a manner sufficient to abrade the at least one surface of the at least one biological tissue;determining, using one or more microprocessors, a similarity or a dissimilarity in information regarding at least one aspect of cellular or tissue abrasion or ablation of at least one biological tissue of at least one first subject to information regarding at least one aspect of cellular or tissue abrasion or ablation of at least one biological tissue of at least one second subject, wherein the at least one second subject attained a clinical outcome following receipt of at least one frozen particle composition;measuring a signal from the at least one tracer agent;communicating in real-time feedback control of the amount of a frozen particle composition delivered to the at least one subject based on the measurement of the signal from the at least one tracer agent; andproviding output information, including at least one of a response signal, a comparison code, a comparison plot, a diagnostic code, a treatment code, a test code, a code indicative of at least one treatment received, a code indicative of at least one prescribed treatment step, a code indicative of at least one vaccination delivered; a code indicative of at least one therapeutic agent delivered; a code indicative of at least one diagnostic agent delivered; a code indicative of at least one interaction of a delivered agent and at least one biological or chemical agent in the subject; a code indicative of at least one dispersion or location of at least one delivered agent; a code indicative of at least one detection material delivered; a code indicative of the depth of penetration of a delivered agent; or a code indicative of the condition of at least one location of an administered frozen particle composition. 29. The method of claim 28, wherein the output information is based on the determination. 30. The method of claim 28, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding quantity of cells or tissue removed or destroyed. 31. The method of claim 28, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding at least one dimension of cellular, tissue, or other material removal or destruction. 32. The method of claim 31, wherein the at least one dimension of cellular, tissue, or other material removal or destruction includes information regarding at least one depth, width, or breadth of cellular, tissue, or other material removal or destruction. 33. The method of claim 28, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding two or more subjects with one or more common attributes. 34. The method of claim 33, wherein the one or more common attributes include genetic attributes, mental attributes, or psychological attributes. 35. The method of claim 33, wherein the one or more common attributes include genotype attributes or phenotype attributes. 36. The method of claim 33, wherein the one or more common attributes include at least one of height; weight; medical diagnosis; familial background; results on one or more medical tests; ethnic background; body mass index; age; presence or absence of at least one disease or condition; species; ethnicity; race; allergies; gender; thickness of epidermis; thickness of dermis; thickness of stratum corneum; keratin deposition; collagen deposition; blood vessel condition; skin condition; hair or fur condition; muscle condition; tissue condition; organ condition; nerve condition; brain condition; presence or absence of at least one biological, chemical, or therapeutic agent in the subject; pregnancy status; lactation status; genetic profile; proteomic profile; partial or whole genetic sequence; partial or whole proteomic sequence; medical history; lymph condition, or blood condition. 37. The method of claim 28, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding at least one cellular or tissue source. 38. The method of claim 37, wherein the information regarding at least one tissue source includes information regarding at least one abnormal cellular or tissue source. 39. The method of claim 38, wherein the information regarding at least one cellular or tissue source includes information regarding at least one type of cell or tissue. 40. The method of claim 28, wherein the at least one frozen particle composition includes at least one of polyethylene glycol, acetone, ethyl acetate, dimethyl sulfoxide, dimethyl formamide, dioxane, hexamethylphosphorotriamide, perfluorohydrocarbon, methanol, ethanol, tert-butyl alcohol, formic acid, hydrogen fluoride, ammonia, acetic acid, benzene, carbon tetrachloride, acetonitrile, hexane, methylene chloride, carboxylic acid, saline, Ringer's solution, lactated Ringer's solution, Hartmann's solution, acetated Ringer's solution, phosphate buffered solution, TRIS-buffered saline solution, Hank's balanced salt solution, Earle's balanced salt solution, standard saline citrate, HEPES-buffered saline, dextrose, glucose, diethyl ether, nitrogen, carbon dioxide, hydrogen oxide, helium, neon, xenon, krypton, chlorine, bromine, oxygen, air or argon. 41. The method of claim 28, wherein the at least one frozen particle composition includes at least one major dimension of approximately one centimeter or less, approximately one millimeter or less, approximately one micrometer or less, approximately one nanometer or less, or any value therebetween. 42. The method of claim 28, wherein the at least one frozen particle composition includes one or more reinforcement agents. 43. The method of claim 28, wherein the at least one frozen particle composition includes one or more explosive materials. 44. The method of claim 28, wherein the receipt by the second subject of at least one frozen particle composition is pursuant to at least one clinical trial. 45. The method of claim 28, further including creating, using one or more microprocessors, at least one inclusion criterion and at least one exclusion criterion for a clinical trial involving the at least one frozen particle composition. 46. The method of claim 28, further including suggesting, using one or more microprocessors, the inclusion of one or more of the at least one subject in at least one clinical trial. 47. The method of claim 28, further including suggesting, using one or more microprocessors, the exclusion of one or more of the at least one subject in at least one clinical trial. 48. A computer-implemented method, comprising: selecting, using one or more microprocessors, a combination of at least two parameters selected from quality or quantity related to one or more frozen particle compositions that include at least one tracer agent; method of delivery of one or more frozen particle compositions; delivery location of one or more frozen particle compositions; content of one or more frozen particle compositions; timing of delivery of one or more frozen particle compositions; decrease in physical dimension of one or more frozen particle compositions; or time interval between at least two subset deliveries with one or more pluralities of frozen particle compositions;administering with a predetermined velocity the selected plurality of frozen particle compositions to at least one surface of at least one biological tissue of a subject in a manner sufficient to abrade the at least one surface of the at least one biological tissue;comparing, using one or more microprocessors, information regarding at least one aspect of cellular or tissue abrasion or ablation of the at least one biological tissue of at least one subject, and information regarding at least one clinical outcome following receipt by the at least one subject of the at least one frozen particle composition;measuring a signal from the at least one tracer agent,communicating real-time feedback control of the amount of a frozen particle composition delivered to the at least one subject based on the measurement of the signal from the at least one tracer agent;andproviding output information, including at least one of a response signal, a comparison code, a comparison plot, a diagnostic code, a treatment code, a test code, a code indicative of at least one treatment received, a code indicative of at least one prescribed treatment step, a code indicative of at least one vaccination delivered; a code indicative of at least one therapeutic agent delivered; a code indicative of at least one diagnostic agent delivered; a code indicative of at least one interaction of a delivered agent and at least one biological or chemical agent in the subject; a code indicative of at least one dispersion or location of at least one delivered agent; a code indicative of at least one detection material delivered; a code indicative of the depth of penetration of a delivered agent; or a code indicative of the condition of at least one location of an administered frozen particle composition.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (173)
Phillips William T. (San Antonio TX) Klipper Robert W. (San Antonio TX) Timmons James H. (Tacoma WA) Rudolph Alan S. (Bowie MD), 99m TC labeled liposomes.
Smits Georges (Gijzegem-Aalst BEX) Daenekindt Luc (Gijzegem-Aalst BEX) Booten Karl (Geetbets BEX), Agglomerated composition, process for producing it and food products containing the said composition.
Kleiner Fredric (New City NY) Roy PradipK. (Yorktown NY), Apparatus and process for the preparation of gasified confectionaries by pressurized deposit molding.
Opel Alan E. (Monrovia CA) Spivak Philip (Toluca Lake CA) Zadorozhny Oleg (North Hollywood CA), Apparatus for producing and blasting sublimable granules on demand.
Armstrong Jay (1543 Weymouth Cir. ; Apt. 109 Westlake OH 44145) Becker James R. (6272 Mills Creek La. North Ridgeville OH 44039), Blast cleaning system.
Topalian Harry H. (Dover DE) Wyss Clement R. (Lewes DE) Kenyon Ralph E. (Dover DE) Dec Anthony F. (Dover DE), Frozen aerated ready-to-eat gelatin composition.
Kitamura Hiroshi (Shizuoka JPX) Mitsuuchi Masamichi (Shizuoka JPX), Glass-reinforced thermoplastic resin compositions containing the anatase form of titanium dioxide as a white pigmenting.
Brinegar Chris (587 Locksley Rd. Boulder Creek CA 95006) Gilmore James (6385 Camino Verde Dr. San Jose CA 95119) Johnson Michael (6385 Camino Verde Dr. San Jose CA 95119) Walker Nigel (5385 Broadway , Ice-mediated introduction of substances into biological material.
Thomas Dag Horn ; Sandra Marchese Johnson, Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction.
Rahman Aquilur (Gaithersburg MD) Rafaeloff Rafael (Tel-Aviv MD ILX) Husain Syed R. (Gaithersburg MD), Liposome encapsulated taxol and a method of using the same.
Weaver, James C.; Anderson, R. Rox; Herndon, Terry O; Gowrishankar, T. R.; Gift, Elizabeth A.; Gonzalez, Salvador, Localized molecular and ionic transport to and from tissues.
Poulsen, Jens Ulrik; Christensen, Lars Hofmann; Aasmul, S.o slashed.ren, Method and a system for assisting a user in a medical self treatment, said self treatment comprising a plurality of actions.
Power Wendy ; Reed Michael A. ; Frustaci Dominick J. ; Larocque Gerald ; Marchetti Brenda, Method and apparatus for determining quantity of liquid in a container and/or lack of motion thereof.
Westergaard Knud E. (Rolighedsvej 16 9560 Hadsund DKX), Method and apparatus for particle blasting using particles of a material that changes its state.
Frohlich, Hans; Gebhardt, Sabine; Trampusch, Berthold, Method and device for generating a two-phase gas-particle jet, in particular containing CO2 dry ice particles.
Cates Michael C. (Solana Beach CA) Hamm Richard R. (San Diego CA) Lewis Michael W. (Wichita KS) Schmitz Wayne N. (St. Louis MO), Method and system for removing a coating from a substrate using radiant energy and a particle stream.
Sanford John C. (Geneva NY) Wolf Edward D. (Ithaca NY) Allen Nelson K. (Newfield NY), Method for transporting substances into living cells and tissues and apparatus therefor.
Bellhouse Brian J. (Islip GB2) Sarphie David F. (Witney GB2) Greenford John C. (Abingdon GB2), Method of delivering powder transdermally with needless injector.
Costantino Henry R. ; Jaworowicz Warren E. ; Tracy Mark A. ; Beganski Christopher P., Method of producing sub-micron particles of biologically active agents and uses thereof.
Cummins Thomas J. (Rochester NY) Ekeze Tobias D. (Rochester NY), Methods of extracting nucleic acids and PCR amplification without using a proteolytic enzyme.
Rhim Won-Kyu (Pasadena CA) Hyson Michael T. (Glendale CA) Chung Sang-Kun (Diamond Bar CA) Colvin Michael S. (Malibu CA) Chang Manchium (Los Angeles CA), Monodisperse, polymeric microspheres produced by irradiation of slowly thawing frozen drops.
Shih, Hong; Leonte, Oana M.; Daugherty, John E.; Huang, Tuochuan; Goldspring, Gregory J.; May, Michael C., On-line chamber cleaning using dry ice blasting.
Clark ; Jr. William G. (Murrysville PA) Herald John J. (Monroeville PA) Liaw Peter K. (Knoxville TN), Pressurized ferrofluid paint removal system using an electromagnet and eddy current encircling coil to adjust weight per.
Fages Jacques,FRX ; Marty Alain,FRX ; Combes Didier,FRX ; Condoret Jean-Stephane,FRX, Process for treating bone tissue and corresponding implantable biomaterials.
Clauss Steven L. (Manville NJ) Pastel Michael J. (Highland Mills NY) Zawadzki Rainer K. (Wuhan CNX), Stable porfimer sodium compositions and methods for their manufacture.
Boyden, Edward S.; Cook, Daniel B.; Hyde, Roderick A.; Leuthardt, Eric C.; Myhrvold, Nathan P.; Sweeney, Elizabeth A.; Wood, Jr., Lowell L., Systems, devices, and methods for making or administering frozen particles.
Santa Cruz Cathy D. ; Deniston-Korgol Christine L. ; Baugh Barbara I. ; Baugh Alexandria D. ; Baugh Roger D., Weather-proof wrist, forearm, and elbow protectors.
Dean ; Jr. Robert C. (Norwich VT) Silver Frederick H. (Long Valley NJ) Berg Richard A. (Lambertville NJ) Phillips Philip G. (Norwich VT) Runstadler ; Jr. Peter W. (Hanover NH), Weighted collagen microsponge for immobilizing bioactive material.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.